Evidence map›Paper›PMID 30627917›Full record

ArticleDigestive diseases and sciences2019

Hepatic miR-181b-5p Contributes to Glycogen Synthesis Through Targeting EGR1.

Shuyue Wang, Chen Liang, Huihan Ai, Meiting Yang, Jingwen Yi, Lei Liu, Zhenbo Song, Yongli Bao, Yuxin Li, Luguo Sun and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Diagnostic and prognostic values ofNon-coding RNA research · 2023
    Article
  4. Article
  5. Identification of microRNA expression profiles of CD44Archives of gynecology and obstetrics · 2022
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shuyue WangNational Engineering Laboratory for Druggable Gene and Protein Screening, School of Life Sciences, Northeast Normal University, No. 5268, Renmin Road, Changchun, 130024, China.
Chen LiangNational Engineering Laboratory for Druggable Gene and Protein Screening, School of Life Sciences, Northeast Normal University, No. 5268, Renmin Road, Changchun, 130024, China.
Huihan AiNational Engineering Laboratory for Druggable Gene and Protein Screening, School of Life Sciences, Northeast Normal University, No. 5268, Renmin Road, Changchun, 130024, China.
Meiting YangNational Engineering Laboratory for Druggable Gene and Protein Screening, School of Life Sciences, Northeast Normal University, No. 5268, Renmin Road, Changchun, 130024, China.
Jingwen YiResearch Center of Agriculture and Medicine Gene Engineering of Ministry of Education, Northeast Normal University, Changchun, 130024, China.
Lei LiuNational Engineering Laboratory for Druggable Gene and Protein Screening, School of Life Sciences, Northeast Normal University, No. 5268, Renmin Road, Changchun, 130024, China.
Zhenbo SongNational Engineering Laboratory for Druggable Gene and Protein Screening, School of Life Sciences, Northeast Normal University, No. 5268, Renmin Road, Changchun, 130024, China.
Yongli BaoNational Engineering Laboratory for Druggable Gene and Protein Screening, School of Life Sciences, Northeast Normal University, No. 5268, Renmin Road, Changchun, 130024, China.
Yuxin LiNational Engineering Laboratory for Druggable Gene and Protein Screening, School of Life Sciences, Northeast Normal University, No. 5268, Renmin Road, Changchun, 130024, China. liyx486@nenu.edu.cn.
Luguo SunResearch Center of Agriculture and Medicine Gene Engineering of Ministry of Education, Northeast Normal University, Changchun, 130024, China. sunlg388@nenu.edu.cn.
Huiying ZhaoDepartment of Geriatrics, The First Hospital of Jilin University, Changchun, 130021, China. zhaohuiying163@163.com.
Northeast Normal University · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe miR-181 family plays an important role in the regulation of various cellular functions. However, whether miR-181b-5p mediates hepatic insulin resistance remains unknown. In this study, we investigated the effect of miR-181b-5p on the regulation of hepatic glycogen synthesis.

methodsThe miR-181b-5p levels in the livers of diabetic mice were detected by real-time PCR. The glycogen levels and AKT/GSK pathway activation were examined in human hepatic L02 cells and HepG2 cells transfected with miR-181b-5p mimic or inhibitor. The potential target genes of miR-181b-5p were evaluated using a luciferase reporter assay and Western blot analysis. EGR1-specific siRNA and pCMV-EGR1 were used to further determine the role of miR-181b-5p in hepatic glycogen synthesis in vitro. Hepatic inhibition of miR-181b-5p in mice was performed using adeno-associated virus 8 (AAV8) vectors by tail intravenous injection.

resultsThe miR-181b-5p levels were significantly decreased in the serum and livers of diabetic mice as well as the serum of type 2 diabetes patients. Importantly, inhibition of miR-181b-5p expression impaired the AKT/GSK pathway and reduced glycogenesis in hepatocytes. Moreover, upregulation of miR-181b-5p reversed high-glucose-induced suppression of glycogenesis. Further analysis revealed that early growth response 1 (EGR1) was a downstream target of miR-181b-5p. Silencing of EGR1 expression rescued miR-181b-5p inhibition-reduced AKT/GSK pathway activation and glycogenesis in hepatocytes. Hepatic inhibition of miR-181b-5p led to insulin resistance in C57BL/6 J mice.

conclusionWe demonstrated that miR-181b-5p contributes to glycogen synthesis by targeting EGR1, thereby regulating PTEN expression to mediate hepatic insulin resistance.

Indexed as

Insulin ResistanceAdultAnimalsDiabetes Mellitus, Type 2Disease Models, AnimalEarly Growth Response Protein 1FemaleGlycogenHep G2 CellsHumansLiverMaleMice, Inbred C57BLMicroRNAsMiddle AgedPTEN PhosphohydrolaseEarly Growth Response Protein 1EGR1 protein, humanEgr1 protein, mouseGlycogenMicroRNAsMIRN-181 microRNA, humanmirn181 microRNA, mousePTEN PhosphohydrolasePTEN protein, humanEGR1Hepatic glycogenesismiR-181b-5pPTEN

Identifiers

PMID30627917
OpenAlexW2909238362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.